Rush University Medical Center

 

Rush University Medical Center
Avatar

Rush 2020 Update on Lung Cancer & ILD Treatment: Are Patients With ILD at Increased Risk of Complications for Cancer Treatment? How Effective Are Prophylactic Therapies?

By Rush University Medical Center FEATURING Mark Yoder
By Rush University Medical Center FEATURING Mark Yoder
123 views
October 13, 2020
0 Comments
Login to view comments. Click here to Login
Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020
13:56
Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

ALKm NSCLC 1L Management Strategies: What ALK TKIs Are Available? Ho…

Feat. C. Lovly
19:03
Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

Driver Mutations in NSCLC: How Important Is Comprehensive Molecular …

Feat. C. Lovly
16:29
Rush University Medical Center

Rush 2020 Clinical Trial Update on Thoracic Surgery: Is Sublobar Res…

Feat. C. Seder
07:57
Rush University Medical Center

Updates in Lung Cancer Screening: Will New USPTF Guidelines Expand S…

Feat. L. Dowling
06:37
Rush University Medical Center

Rush Update on Lung Cancer Screening During COVID-19: What Are the C…

Feat. L. Dowling
15:08
Rush University Medical Center

Rush 2020 Update on Lung Cancer Diagnosis: Which Minimally Invasive …

Feat. J. Katsis
19:34
Rush University Medical Center

Rush 2020 Update on Lung Cancer & ILD Treatment: Are Patients Wi…

Feat. M. Yoder
11:23
Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

Rush 2020 Updates on Lung Cancer Screening: How Does It Compare to E…

Feat. J. Karush
32:14
Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

Rush 2020 Update on SBRT in Lung Cancer: What Is the Role of Aggress…

Feat. G. Marwaha
13:53
Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

Rush 2020 Update on IO in 1L NSCLC: Is Single Agent PD-1 Antibody th…

Feat. M. Fidler